sizofiran has been researched along with 9,10-dimethyl-1,2-benzanthracene in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Imaishi, K; Kataoka, A; Kumagai, S; Nishida, T; Sugiyama, T; Ushijima, K; Yakushiji, M | 1 |
| Aleem, E; Baddour, N; Daba, A; El-Saadani, M; Mansour, A | 1 |
2 other study(ies) available for sizofiran and 9,10-dimethyl-1,2-benzanthracene
| Article | Year |
|---|---|
Combination treatment with cisplatin and schizophyllan for 7,12-dimethylbenz(a)anthracene-induced rat ovarian adenocarcinoma.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinogens; Cisplatin; Female; Ovarian Neoplasms; Rats; Rats, Inbred F344; Sizofiran | 1995 |
Schizophyllan inhibits the development of mammary and hepatic carcinomas induced by 7,12 dimethylbenz(α)anthracene and decreases cell proliferation: comparison with tamoxifen.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspase 3; Cell Proliferation; Female; Immunohistochemistry; Liver Neoplasms, Experimental; Mammary Neoplasms, Experimental; Mice; Proliferating Cell Nuclear Antigen; Receptors, Estrogen; Schizophyllum; Sizofiran; Survival Analysis; Tamoxifen | 2012 |